CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Prime Medicine, Inc. (PRME) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Prime Medicine, Inc. (PRME)

Biological Products, (No Diagnostic Substances) · market cap $597M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Prime Medicine, Inc. (PRME) is a Cambridge-based gene therapy company built around prime editing technology, with its lead asset PM359 in Phase 2 for Chronic Granulomatous Disease (CGD). The company carries a ~$551M market cap but faces an acute near-term financing crisis with only $64.1M in cash and an estimated 4.5-month runway as of July 2026.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
PM359Phase 2Chronic Granulomatous Disease
PM577aPhase 2Wilson Disease
Price & technical context
3-month
+13.3%
6-month
+30.2%
12-month
+8.2%
52-wk range
$2.70–$5.36
vs 50-day MA
+2.9%
vs 200-day MA
+9.5%
Realized vol
89.6%
Max drawdown
-73.8%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for PRME (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.